In the options pits, NVAX has already seen quadruple the overall options volume it typically sees in an entire session, with ...

Novavax finally won approval of a Covid-19 vaccine after facing setback after setback that caused the stock to plunge more ...

Novavax originally showed its vaccine was safe and effective in a 30,000-person clinical trial. The FDA had been on track to ...

JP Morgan analyst Puneet Jain upgraded CI&T from Neutral to Overweight and announced a $7 price target. CI&T shares jumped 8.2% to $6.60 on Monday. Markets expect rate cuts — but your earnings don’t ...

Novavax Inc. jumped after US regulators fully approved its Covid vaccine, easing investors’ concerns after the clearance was ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

WASHINGTON — Robert F. Kennedy Jr. clinched the political support needed to become the nation’s top health official by ...

Novavax received Food and Drug Administration approval for its new, protein-based COVID-19 vaccine, and shares jumped 25% at the opening bell Monday.

In other vaccine news, Health Secretary Robert F. Kennedy Jr. has officially ordered placebo testing on new vaccines, a change that experts claim will be costly and — harkening back to polio vaccine ...

At long last, Novavax has secured a full FDA approval for its protein-based COVID-19 vaccine, though not in the broad ...

The U.S. Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for Novavax Inc.’s Nuvaxovid.

Novavax (NVAX) shares climbed more than 17% premarket on Monday after the long-delayed approval of its COVID-19 vaccine from ...